NasdaqCM:OCGNBiotechs
Ocugen (OCGN) Is Down 7.0% After Mixed Q3 Results and Gene Therapy Milestones – What's Changed
Ocugen, Inc. recently reported its third-quarter 2025 earnings, showing revenue of US$1.75 million and a net loss of US$20.05 million, alongside notable progress in its gene therapy pipeline and business development activities.
Significantly, the company advanced its OCU400 program toward Phase 3 enrollment completion, secured a South Korean licensing deal, and extended its cash runway, highlighting material updates across both clinical and financial fronts.
We'll examine how Ocugen's...